Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… the Department of Medicines and Health Technologies (MTS - Univ. Paris-Saclay/INRAE/CEA) . These are Daniel Gillet, … funding the following month. In June 2025, the start-up was selected by Bpifrance to join the deep tech community. … in proving that this factor is responsible for the onset and progression of CGN, and therefore constitutes a …
Published on: